Oncology and Hematology

Head prof. Elona Juozaitytė, MD, PhD
Address: Eivenių Str. 2, LT-50161, Kaunas 
Phone: +37037327326
E-mail: onkologijos.klinika@kaunoklinikos.lt

The main functions of the Department of Oncology and Hematology are to provide patients with qualified and specialized services in oncology and hematology. The Department of Oncology and Hematology is involved into clinical, educational and scientific activities. Today oncology in Kaunas is a multimodality cancer care system. Oncology and hematology department successfully integrates different hospital departments involved in cancer diagnosis, surgical and other treatment modalities. Today radiotherapy in Kaunas is part of multimodality cancer care system. Now we are running four modern linacs, equipped with MLC‘s and CBCT. Our patients could benefit from modern treatment approaches like IMRT, IGRT or stereotactic intracranial and body radiotherapy. As well extensive HDR brachytherapy programme runs in our hospital, including gynaecological, prostate, head&neck, breast applications.
Over 6000 cancer patients are treated in Oncology and hematology department every year. There is a multidisciplinary collaboration in cancer care among 24 different clinical departments in the Hospital of LUHS Kauno klinikos.

The scientific research is organised in clinical departments and in oncology research laboratory. The Oncology Research Laboratory was founded in 2009. A team of biologists and geneticists was formed and the laboratory began to work in autumn of 2011. Main research areas are prognostic and predictive molecular markers of solid tumors, radiobiology research, molecular markers of myeloproliferative and lymphoproliferative diseases. Our clinical oncology research fields, however, are relatively broad. Personalized medicine research in the Oncology institute of Lithuanian University of Health Sciences is focused on studying the impact of genetic factors on pathogenesis of different oncological diseases. We aim to assess the predictive and prognostic value of genetic factors for both solid tumours and hematological malignancies. These biomarkers are believed to allow faster diagnosis and improve our knowledge on personalized cancer patient prognosis and treatment. Main research areas are prognostic and predictive molecular markers of solid tumors, radiobiology research, molecular markers of myeloproliferative and lymphoproliferative diseases.

Prognostic and predictive molecular markers of solid tumors.
Radiobiology research.
Molecular markers of myeloproliferative and lymphoproliferative diseases.

X